CMN Weekly (30 May 2025) - Your Weekly CRISPR...
CMN Weekly
May. 30, 2025
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Generation Bio
Company Type: Therapeutic development
Main focus: Developing novel in vivo genetic medicines for a range of diseases
Company stage: Pre-clinical
Diseases: Rare metabolic diseases, immune disorders, and others
Genome-editing tool: Closed-ended DNA (ceDNA) gene therapy technology
Funding stage: Post-IPO Equity
Location: Cambridge, Massachusetts, USA
Website: generationbio.com
Pipeline:
Partners:
Generation Bio is a pre-clinical stage biotechnology company developing non-viral gene therapies using its proprietary closed-ended DNA (ceDNA) technology. Headquartered in Cambridge, Massachusetts, the company focuses on developing 'redosable', in vivo treatments for various genetic diseases, including rare metabolic and immune disorders. Their platform delivers genetic material without genome edits using a proprietary selective cell-targeted lipid nanoparticle (ctLNP) delivery platform that aims to provide solutions for broader therapeutic applications.
